NasdaqGS:UTHRBiotechs
How United Therapeutics' (UTHR) Q2 Earnings Miss and Tyvaso Growth Shift Its Investment Story
United Therapeutics recently reported second quarter results, revealing double-digit year-over-year revenue growth led by its Tyvaso DPI franchise, yet both revenue and non-GAAP earnings per share fell short of Wall Street forecasts.
An interesting detail is management’s emphasis on upcoming clinical milestones, particularly the TETON 2 Phase III data for idiopathic pulmonary fibrosis, as a potential catalyst for future growth.
We’ll now consider how United Therapeutics’ financial miss,...